Eniluracil is a small molecule commercialized by Processa Pharmaceuticals, with a leading Phase III program in Metastatic Colorectal Cancer. According to Globaldata, it is involved in 22 clinical trials, of which 17 were completed, 2 are ongoing, 1 is planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Eniluracil’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Eniluracil is expected to reach an annual total of $15 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Eniluracil is under development for the treatment of metastatic breast cancer, metastatic colorectal cancer and pancreatic cancer. The drug candidate is administered through oral route. It targets dihydropyrimidine dehydrogenase. It was also under development for hepatocellular carcinoma , non-small cell lung carcinoma, gastric cancer, cervical cancer, prostate cancer.
Processa Pharmaceuticals Overview
Processa Pharmaceuticals, formerly Heatwurx, is a biopharmaceutical company which develops and commercializes drugs for the treatment of skin diseases and various cancer types. It is investigating its lead product candidate: PCS499 to treat necrobiosis lipoidica (NL), a chronic, disfiguring skin disorder; and to treat the side effects of radiation in patients with head and neck cancer. The PCS499 holds Orphan Drug designation for the treatment of NL. The company is evaluating PCS100, an anti-fibrotic and anti-inflammatory drug against idiopathic pulmonary fibrosis (IPF) and primary glomerulonephritis. It operates in the US. Processa Pharmaceuticals is headquartered in Baltimore, Maryland, the US.
The operating loss of the company was US$12 million in FY2021, compared to an operating loss of US$15.1 million in FY2020. The net loss of the company was US$11.4 million in FY2021, compared to a net loss of US$14.4 million in FY2020.
For a complete picture of Eniluracil’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.